The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
详细信息 查看全文
- 作者：Joel D Pearson (1)
Zubair Mohammed (1)
Julinor T C Bacani (2)
Raymond Lai (2)
Robert J Ingham (1) - 刊名：BMC Cancer
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：502KB
- 参考文献：1. Delsol G, Falini B, Muller-Hermelink H, Campo E, Jaffe E, Gascoyne R, Stein H, Kinney M: Anaplastic Large Cell Lymphoma (ALCL), ALK-positive. In / International Agency for Research on Cancer (IARC). Edited by: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J. IARC Press, Lyon, Francec; 2008:312鈥?16.
2. Amin HM, Lai R: Pathobiology of ALK+ anaplastic large-cell lymphoma. / Blood 2007, 110:2259鈥?267. CrossRef
3. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. / Nat Rev Cancer 2008, 8:11鈥?3. CrossRef
4. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, / et al.: A mouse model for EML4-ALK-positive lung cancer. / Proc Natl Acad Sci U S A 2008, 105:19893鈥?9897. CrossRef
5. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, / et al.: Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. / Cancer Res 2008, 68:4971鈥?976. CrossRef
6. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, / et al.: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. / Clin Cancer Res 2008, 14:4275鈥?283. CrossRef
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, / et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. / N Engl J Med 2010, 363:1693鈥?703. CrossRef
8. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA: TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. / Am J Pathol 2000, 157:377鈥?84. CrossRef
9. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ: Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. / Cancer Res 1999, 59:2776鈥?780.
10. Butrynski JE, D鈥橝damo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, / et al.: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. / N Engl J Med 2010, 363:1727鈥?733. CrossRef
11. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin鈥檚 lymphoma. / Science 1994, 263:1281鈥?284. CrossRef
12. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S: Hyperphosphorylation of a novel 80鈥塳Da protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. / Oncogene 1994, 9:1567鈥?574.
13. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). / Proc Natl Acad Sci U S A 1996, 93:4181鈥?186. CrossRef
14. Bischof D, Pulford K, Mason DY, Morris SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin鈥檚 lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. / Mol Cell Biol 1997, 17:2312鈥?325.
15. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A: The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. / Exp Hematol 2006, 34:1670鈥?679. CrossRef
16. Bonvini P, Gastaldi T, Falini B, Rosolen A: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. / Cancer Res 2002, 62:1559鈥?566.
17. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A: Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. / Cancer Res 2004, 64:3256鈥?264. CrossRef
18. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS: Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. / Proteomics 2007, 7:2603鈥?616. CrossRef
19. Trepel J, Mollapour M, Giaccone G, Neckers L: Targeting the dynamic HSP90 complex in cancer. / Nat Rev Cancer 2010, 10:537鈥?49. CrossRef
20. Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. / Nat Rev Mol Cell Biol 2010, 11:515鈥?28. CrossRef
21. Theodoraki MA, Kunjappu M, Sternberg DW, Caplan AJ: Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context. / Exp Cell Res 2007, 313:3851鈥?858. CrossRef
22. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, / et al.: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. / Cancer Res 2010, 70:9827鈥?836. CrossRef
23. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, / et al.: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. / Oncogene 2011, 30:2581鈥?586. CrossRef
24. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. / Proc Natl Acad Sci U S A 2011, 108:7535鈥?540. CrossRef
25. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, / et al.: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. / J Clin Oncol 2010, 28:4953鈥?960. CrossRef
26. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, / et al.: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. / Cancer Res 2010, 70:10038鈥?0043. CrossRef
27. Ratajczak T, Ward BK, Minchin RF: Immunophilin chaperones in steroid receptor signalling. / Curr Top Med Chem 2003, 3:1348鈥?357. 51934">CrossRef
28. Ratajczak T, Ward BK, Cluning C, Allan RK: Cyclophilin 40: an Hsp90-cochaperone associated with apo-steroid receptors. / Int J Biochem Cell Biol 2009, 41:1652鈥?655. CrossRef
29. Davies TH, Sanchez ER: Fkbp52. / Int J Biochem Cell Biol 2005, 37:42鈥?7. CrossRef
30. Li L, Lou Z, Wang L: The role of FKBP5 in cancer aetiology and chemoresistance. / Br J Cancer 2011, 104:19鈥?3. CrossRef
31. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG: Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. / Endocrinology 2000, 141:4107鈥?113. CrossRef
32. Riggs DL, Roberts PJ, Chirillo SC, Cheung-Flynn J, Prapapanich V, Ratajczak T, Gaber R, Picard D, Smith DF: The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. / EMBO J 2003, 22:1158鈥?167. CrossRef
33. Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T: FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. / J Biol Chem 2005, 280:4609鈥?616. CrossRef
34. Warrier M, Hinds TD, Ledford KJ, Cash HA, Patel PR, Bowman TA, Stechschulte LA, Yong W, Shou W, Najjar SM, Sanchez ER: Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. / Endocrinology 2010, 151:3225鈥?236. CrossRef
35. Davies TH, Ning YM, Sanchez ER: Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. / Biochemistry 2005, 44:2030鈥?038. CrossRef
36. Scroggins BT, Prince T, Shao J, Uma S, Huang W, Guo Y, Yun BG, Hedman K, Matts RL, Hartson SD: High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients. / Biochemistry 2003, 42:12550鈥?2561. CrossRef
37. Nair SC, Toran EJ, Rimerman RA, Hjermstad S, Smithgall TE, Smith DF: A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor. / Cell Stress Chaperones 1996, 1:237鈥?50. CrossRef
38. Duina AA, Chang HC, Marsh JA, Lindquist S, Gaber RF: A cyclophilin function in Hsp90-dependent signal transduction. / Science 1996, 274:1713鈥?715. CrossRef
39. Periyasamy S, Hinds T, Shemshedini L, Shou W, Sanchez ER: FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. / Oncogene 2010, 29:1691鈥?701. CrossRef
40. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. / EMBO J 2002, 21:4104鈥?113. CrossRef
41. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX, Medeiros LJ: JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. / Mod Pathol 2005, 18:1365鈥?370. CrossRef
42. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M, Freissmuth M, Stoxreiter R, Theussl HC, Parzer SB, / et al.: JunB inhibits proliferation and transformation in B-lymphoid cells. / Blood 2003, 102:4159鈥?165. CrossRef
43. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, / et al.: The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. / Blood 2007, 110:3374鈥?383. CrossRef
44. Hsu FY, Johnston PB, Burke KA, Zhao Y: The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. / Cancer Res 2006, 66:9002鈥?008. CrossRef
45. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, Abraham LJ, Watanabe T, Horie R: JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. / Cancer Res 2005, 65:7628鈥?634.
46. Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ: NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. / Int J Clin Exp Pathol 2011, 4:124鈥?33.
47. Kinney MC, Higgins RA, Medina EA: Anaplastic large cell lymphoma: twenty-five years of discovery. / Arch Pathol Lab Med 2011, 135:19鈥?3.
48. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. / Mol Cancer Ther 2007, 6:3314鈥?322. CrossRef
49. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, / et al.: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. / Cancer Res 2008, 68:3389鈥?395. CrossRef
50. Ingham RJ, Raaijmakers J, Lim CS, Mbamalu G, Gish G, Chen F, Matskova L, Ernberg I, Winberg G, Pawson T: The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor. / J Biol Chem 2005, 280:34133鈥?4142. CrossRef
51. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. / Methods 2001, 25:402鈥?08. CrossRef
52. Kumar P, Ward BK, Minchin RF, Ratajczak T: Regulation of the Hsp90-binding immunophilin, cyclophilin 40, is mediated by multiple sites for GA-binding protein (GABP). / Cell Stress Chaperones 2001, 6:78鈥?1. CrossRef
53. Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplastic large-cell lymphoma. / N Engl J Med 2011, 364:775鈥?76. CrossRef
54. Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, Matsui Y, Yoshino M, Shingyoji M, Itakura M, / et al.: ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. / Lung Cancer 2012, 75:66鈥?2. CrossRef
55. Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H, Nagatomo I, Hoshino S, Takeda Y, Kida H, / et al.: Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. / Cancer Sci 2011, 102:1602鈥?604. CrossRef
56. Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, Donella-Deana A, Pinna LA, Gambacorti-Passerini C: Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. / J Biol Chem 2008, 283:3743鈥?750. CrossRef
57. Wang P, Wu F, Ma Y, Li L, Lai R, Young LC: Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. / J Biol Chem 2010, 285:95鈥?03. CrossRef
58. Nair SC, Rimerman RA, Toran EJ, Chen S, Prapapanich V, Butts RN, Smith DF: Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. / Mol Cell Biol 1997, 17:594鈥?03.
59. Barent RL, Nair SC, Carr DC, Ruan Y, Rimerman RA, Fulton J, Zhang Y, Smith DF: Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. / Mol Endocrinol 1998, 12:342鈥?54. CrossRef
60. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. / J Immunol 2002, 168:466鈥?74.
61. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. / Oncogene 2002, 21:1038鈥?047. 5152">CrossRef
62. Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR, Reddy DR, Holskin BP, Angeles TS, Underiner TL, / et al.: Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. / Blood 2006, 107:1617鈥?623. CrossRef
63. Schaefer TS, Sanders LK, Park OK, Nathans D: Functional differences between Stat3alpha and Stat3beta. / Mol Cell Biol 1997, 17:5307鈥?316.
64. Schaefer LK, Wang S, Schaefer TS: c-Src activates the DNA binding and transcriptional activity of Stat3 molecules: serine 727 is not required for transcriptional activation under certain circumstances. / Biochem Biophys Res Commun 1999, 266:481鈥?87. CrossRef
65. Kaptein A, Paillard V, Saunders M: Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. / J Biol Chem 1996, 271:5961鈥?964. CrossRef
66. Romano S, D鈥橝ngelillo A, Pacelli R, Staibano S, De Luna E, Bisogni R, Eskelinen EL, Mascolo M, Cali G, Arra C, Romano MF: Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. / Cell Death Differ 2010, 17:145鈥?57. CrossRef
67. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L: FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. / Cancer Cell 2009, 16:259鈥?66. CrossRef
68. Leverson JD, Ness SA: Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. / Mol Cell 1998, 1:203鈥?11. CrossRef
69. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH: The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. / Mol Cell Biol 1998, 18:1517鈥?524.
70. Park MS, Chu F, Xie J, Wang Y, Bhattacharya P, Chan WK: Identification of cyclophilin-40-interacting proteins reveals potential cellular function of cyclophilin-40. / Anal Biochem 2011, 410:257鈥?65. CrossRef
71. Smith MR, Willmann MR, Wu G, Berardini TZ, Moller B, Weijers D, Poethig RS: Cyclophilin 40 is required for microRNA activity in Arabidopsis. / Proc Natl Acad Sci U S A 2009, 106:5424鈥?429. CrossRef
72. Smith JR, Clarke PA, de Billy E, Workman P: Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. / Oncogene 2009, 28:157鈥?69. CrossRef
73. Wu F, Wang P, Young LC, Lai R, Li L: Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. / Am J Pathol 2009, 174:361鈥?70. CrossRef
74. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/229/prepub - 作者单位：Joel D Pearson (1)
Zubair Mohammed (1)
Julinor T C Bacani (2)
Raymond Lai (2)
Robert J Ingham (1)
1. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, T6G 2E1, Canada
2. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, T6G 2B7, Canada - ISSN：1471-2407
文摘
Background Anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) is a T cell lymphoma defined by the presence of chromosomal translocations involving the ALK tyrosine kinase gene. These translocations generate fusion proteins (e.g. NPM-ALK) with constitutive tyrosine kinase activity, which activate numerous signalling pathways important for ALK+ ALCL pathogenesis. The molecular chaperone heat shock protein-90 (Hsp90) plays a critical role in allowing NPM-ALK and other signalling proteins to function in this lymphoma. Co-chaperone proteins are important for helping Hsp90 fold proteins and for directing Hsp90 to specific clients; however the importance of co-chaperone proteins in ALK+ ALCL has not been investigated. Our preliminary findings suggested that expression of the immunophilin co-chaperone, Cyclophilin 40 (Cyp40), is up-regulated in ALK+ ALCL by JunB, a transcription factor activated by NPM-ALK signalling. In this study we examined the regulation of the immunophilin family of co-chaperones by NPM-ALK and JunB, and investigated whether the immunophilin co-chaperones promote the viability of ALK+ ALCL cell lines. Methods NPM-ALK and JunB were knocked-down in ALK+ ALCL cell lines with siRNA, and the effect on the expression of the three immunophilin co-chaperones: Cyp40, FK506-binding protein (FKBP) 51, and FKBP52 examined. Furthermore, the effect of knock-down of the immunophilin co-chaperones, either individually or in combination, on the viability of ALK+ ALCL cell lines and NPM-ALK levels and activity was also examined. Results We found that NPM-ALK promoted the transcription of Cyp40 and FKBP52, but only Cyp40 transcription was promoted by JunB. We also observed reduced viability of ALK+ ALCL cell lines treated with Cyp40 siRNA, but not with siRNAs directed against FKBP52 or FKBP51. Finally, we demonstrate that the decrease in the viability of ALK+ ALCL cell lines treated with Cyp40 siRNA does not appear to be due to a decrease in NPM-ALK levels or the ability of this oncoprotein to signal. Conclusions This is the first study demonstrating that the expression of immunophilin family co-chaperones is promoted by an oncogenic tyrosine kinase. Moreover, this is the first report establishing an important role for Cyp40 in lymphoma.